Extracellular Forms of Aβ and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity.

Cell Reports
Neng-Wei HuMichael J Rowan

Abstract

The early stages of Alzheimer's disease are associated with synaptic dysfunction prior to overt loss of neurons. To identify extracellular molecules that impair synaptic plasticity in the brain, we studied the secretomes of human iPSC-derived neuronal models of Alzheimer's disease. When introduced into the rat brain, secretomes from human neurons with either a presenilin-1 mutation, amyloid precursor protein duplication, or trisomy of chromosome 21 all strongly inhibit hippocampal long-term potentiation. Synaptic dysfunction caused by presenilin-1 mutant and amyloid precusor protein duplication secretomes is mediated by Aβ peptides, whereas trisomy of chromosome 21 (trisomy 21) neuronal secretomes induce dysfunction through extracellular tau. In all cases, synaptotoxicity is relieved by antibody blockade of cellular prion protein. These data indicate that human models of Alzheimer's disease generate distinct proteins that converge at the level of cellular prion protein to induce synaptic dysfunction in vivo.

Citations

Feb 16, 2019·Acta Neuropathologica Communications·Santosh JadhavNorbert Zilka
Dec 19, 2019·Tissue Engineering. Part B, Reviews·Richard JeskeYan Li
May 20, 2020·Scientific Reports·Shahzad AhmadCornelia M van Duijn
Jun 4, 2020·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Julbert CaneusJames J Hickman
Aug 16, 2019·Acta Neuropathologica·Luis Aragão GomesDietmar Rudolf Thal
Jul 12, 2019·Frontiers in Neuroscience·Camille PernègreNicole Leclerc
Sep 24, 2020·International Journal of Molecular Sciences·Juan Antonio Garcia-LeonAntonia Gutierrez
Mar 13, 2020·Neurochemical Research·Yan YanHaibing Yu
Jun 27, 2019·Progress in Neurobiology·Thomas W RöslerGünter U Höglinger
Oct 18, 2020·Molecular and Cellular Neurosciences·Giovanna CeniniOliver Brüstle
Feb 9, 2021·Reviews in the Neurosciences·Asiamah Ernest AmponsahHuixian Cui
Nov 5, 2019·Biochimica Et Biophysica Acta. Molecular Basis of Disease·G AmadoroP Calissano
Apr 10, 2021·Acta Neuropathologica Communications·Ivan Martinez-ValbuenaMaría-Rosario Luquin
May 21, 2021·Drug Discovery Today·J Mark Treherne, Gillian R Langley
Jun 5, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ou QiaoWenyuan Gao
Jun 29, 2021·Journal of Alzheimer's Disease : JAD·Weina YaoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Aug 14, 2021·European Journal of Medicinal Chemistry·Olmo Martín-CámaraJ Carlos Menéndez

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
immunodepletion
size
ELISAs
size fractionation
Immunoprecipitation
immunodeplete
immunoprecipitations

Software Mentioned

GraphPad
Prism

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.